cancers Cancers Cancers cancers 2072-6694 MDPI 10.3390/cancers2020955 cancers-02-00955 Review Systemic Therapy of Non-Resectable Metastatic Melanoma Orouji Azadeh Goerdt Sergij Utikal Jochen * Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany; E-Mails: azadeh.orouji@umm.de (A.O.); sergij.goerdt@umm.de (S.G.) Author to whom correspondence should be addressed; E-Mail: Jochen.Utikal@umm.de; Tel.: +49 621 383 4461; Fax: +49 621 383 3815. 26 05 2010 06 2010 2 2955969 08 03 2010 11 05 2010 12 05 2010 © 2010 by the authors; licensee MDPI, Basel, Switzerland. 2010

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.

 melanoma metastatic chemotherapy targeted therapy small molecules 1. Introduction

Melanoma is an aggressive tumor with a continuously growing incidence worldwide. Depending on tumor thickness, ulceration and lymphocytic infiltration at the time of diagnosis, 20–25% of all primary melanoma will spread [1,2]. In case of distant metastatic melanoma, with the exception of rare cases of surgery for oligometastatic disease, the prognosis is fatal with median survival times between six and twelve months. It has a three-year survival rate of only 10–15% [3]. Here we summarize therapeutic options in distant metastatic disease.

 2. Chemotherapy

In cases of non-resectable metastatic melanoma, systemic chemotherapy is a therapeutic option, besides radiotherapy. Chemotherapeutic agents are cytotoxic anticancer drugs that impair cell division, resulting in the death of rapidly dividing cells.

Single-agent chemotherapy produces responses in 10–25% of patients with advanced melanoma, although there is no evidence that this translates into a survival advantage. We see complete responses only in about 2% of the cases. The median survival associated with chemotherapy is nine months. 13% of patients are alive at two years [4]. Compounds including dacarbazine (DTIC), temozolomide, fotemustine and vindesine are commonly used (see Table 1).

cancers-02-00955-t001_Table 1

Cytotoxic drugs used in the therapy of distant metastatic melanoma.

Chemotherapy
Single-agent chemotherapy
Dacarbazine (DTIC) 200–250 mg/m2/day i. v., 5 daily doses 800–1200 mg/m2 i. v., every 3–4 weeks
Temozolomide 150–200 mg/m2 p. o. 5 daily doses (day 1–5), every 4 weeks 150 mg/m2 p. o., day 1–7, then 7 days pause (biweekly)
Fotemustine 100 mg/m2 i. V. day 1 and 8 and 15, then 5 weeks pause, continuation every 3 weeks
Vindesine 3 mg/m2 i. v., every 2 weeks
Combination chemotherapy
Carboplatin/ Paclitaxel Carboplatin AUC 6 i. v. day 1 Paclitaxel 225 mg/m2 i. v. day 1 every 3 weeks
Gemcitabine/ Treosulfan Gemcitabine 1000 mg/m2 i. v. day 1 and 8 Treosulfan 3500 mg/m2 i. v. day 1 and 8 every 3 weeks
BHD BCNU 150 mg/m2 i. v. day 1, every 2 cycles Hydroxyurea 1500 mg/m2 p. o. day 1–5 Dacarbazine 150 mg/m2 i. v. day 1–5 every 4 weeks
BOLD Bleomycin 15 mg/m2 i. v., day 1 and 4 Vincristine 1 mg/m2 i. v. day 1 and 5 CCNU 80 mg/m2 p. o. day 1 Dacarbazine 200 mg/m2 i. v. day 1–5 every 4 weeks
DVP Dacarbazine 450 mg/m2 i. v., day 1 and 8 Vindesine 3 mg/m2 i. v., day 1 and 8 Cisplatin 50 mg/m2 i. v., day 1 and 8, every 3–4 weeks
2.1. Dacarbazine (DTIC)

In 1975, dacarbazine (DTIC) became the first US Food and Drug Administration (FDA) approved chemotherapeutic agent for the treatment of metastatic melanoma. As a single agent, dacarbazine was most commonly used even when it had not been formally compared with other agents or with observation alone. The usual dose is 800–1200 mg/m2 every 3–4 weeks (given either in one dose or in five doses of 200–250 mg/m2 on different days). The response rates with dacarbazine are 15–25%, with the median response duration of 5–6 months, but less than 5% of complete responses. Long-term follow-up of patients treated with dacarbazine alone shows less than 2% survival rate for six years [5,6].

 2.2. Temozolomide

Dacarbazine can also be substituted with temozolomide, an orally available analog of dacarbazine, because of its convenience of adminstration. This substance has the advantage of central nervous system penetration. Temozolomide has shown an equal efficacy to that of dacarbazine in a phase III trial at a dose of 200 mg/m2/day for five days every 28 days. Recent results from a large, randomized phase III trial showed no differences in overall survival, progression-free survival and overall response rate between temozolomide arm and dacarbazine arm. This trial examined the efficacy of an extended schedule of temozolomide (week on–week off, 150 mg/m2/day for seven days, repeated every 14 days) compared with standard dose single-agent dacarbazine. Temozolomide was very well tolerated and showed an improvement in the quality of life, resulting in large use of temozolomide for the treatment of metastatic melanoma [7].

2.3. Fotemustine

Fotemustine, a nitrosourea, is probably the most active one of this group in metastatic melanoma. The nitrosoureas can cross the blood-brain barrier. Fotemustine has been widely tested in Europe and has shown an overall response of 20–25%, including 5–8% of complete response rates. It was the first drug showing significant efficacy in brain metastases [8,9]. In a study comparing foremustine to dacarbazine, fotemustine produced a higher overall response rate than dacarbazine. However, response duration (time to disease progression and overall survival) was not statistically significant. Interestingly, in patients without brain metastasis at inclusion, the median time to brain metastasis was longer in fotemustine comparing to dacarbazine (22.7 months versus 7.2 months). This trial showed no significant difference in terms of quality of life between both arms [10].

 2.4. Vindesine

Vindesine is a vinca alkaloid used as a single agent therapy as well as in polychemotherapy in patients with metastatic melanoma. The vinca alkaloids block cell division in metaphase. The main side effects of vindesine are nephrotoxicity and neurotoxicity. A mild myelosuppression is another side effect of vindesine [11].

 2.5. Polychemotherapy

The poor efficacy of the single agent chemotherapy led to the evaluation of polychemotherapy in the 1980s to improve outcome and enhance response rates in patients with metastatic melanoma. The first combinations added nitrosourea, vinca alkaloids or platinum to dacarbazine, failing to result in any significant benefit compared with dacarbazine alone, except for a slight increase of response rates. Other more aggressive polychemotherapy regimens such as BHD (BCNU, hydroxyurea, and dacarbazine) and BOLD (bleomycin, vincristine, CCNU, and dacarbazine) were used, and resulted in higher response rates without any survival advantage. In a phase II trial with the combination of dacarbazine, cisplatinum and vindesine (DVP or CVD), a response rate of 40% was obtained, including 4% of complete response [12]. In a randomized study on 150 patients comparing CVD to dacarbazine, the response rate was higher in the CVD arm as compared to the dacarbazine arm (19% to 14%), without any differences in either response duration or survival. However, increased toxicity has been observed [13]. The combination of tamoxifen and dacarbazine was tested in a small phase III study. It demonstrated an improvement of response and survival compared to dacarbazine alone [14]. However, other large randomized studies did not support this result. The reported efficacy of the combination of paclitaxel and carboplatin used in the therapy of metastatic melanoma in recent years was one of the more unexpected developments.

The other chemotherapy combination is gemcitabine and treosulfan. To evaluate an in vitro test system providing information on the drug sensitivity profile of melanoma cells, Ugurel et al. examined tumor tissue specimens from metastatic melanoma patients with an ATP-based chemosensitivity assay (ATP-TCA). In the chemosensitivity testing in 31 metastatic melanoma patients, the highest sensitivity was detected for this combination. 76% of the tissue samples revealed high sensitivity and 10% resistance [15]. Chemosensitive patients showed an increased overall survival of 14.6 months compared with 7.4 months in chemoresistant patients [16].

Huncharek et al. reported in a meta-analysis comparing two or three drug combination regimens with dacarbazine alone, that there was no advantage for the combination chemotherapy in terms of response or survival. Treatment decisions remain controversial, and quality of life and toxicity issues from treatment assume greater importance [17].

As a first-line therapy, polychemotherapy did not show significant advantages for prolongation of survival compared to single agent therapy; hence it is more toxic. As treatment in metastatic non-operable malignant melanoma is primarily palliative, the effect of any regimen on the quality of life must be carefully weighed [18].

 3. Immunotherapy

The Term “immunotherapy” is used for non-specific as well as specific immunomodulation that encompasses a number of different approaches, summarized below.

3.1. Cytokines

The most widely used immunomodulating drugs in metastatic melanoma are Interleukin 2 (IL-2) and Interferon α (IFN-α). An overall objective response rate of 16% and a complete response in 6% of patients treated with high-dose IL-2 have been reported [19]. IL-2 can cause severe hypotension and vascular leak syndrome, resulting in interstitial and pulmonary edema, renal and hepatic dysfunction, cardiovascular failure, neurological disturbances, nausea, vomiting and thrombocytopenia [20]. The significant toxicity of the treatment with IL-2 (Proleukin) has limited its use to selected patients with good organ function who are treated by experienced clinicians at selected specialized centers [2].

Numerous studies have demonstrated that IFN-α has antiproliferative and immunomodulatory effects, including the inhibition of angiogenesis [21], the increase of major histocompatibility complex class I antigen expression and the infiltration of CD4+ T cells into melanomas [22]. In a metastatic situation, single agent IFN-α showed approximately 15% of responses with less than 5% of complete response rates and median response duration between six and nine months, with a maximum of twelve months for the best studies [23]. These response rates, while encouraging, were not significant enough to lead to its widespread use in the treatment of metastatic melanoma. However, observations that patients with non-visceral disease were more likely to response suggested that the use of IFN-α may demonstrate a greater impact in patients with micrometastasis [23,24].

3.2. Monoclonal Antibodies

Anti-cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4)

Activation of naïve T cells requires recognition of the antigen by the T cell receptor (TCR) and provision of costimulatory signals. CTLA-4 is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The pivotal role of CTLA-4 in regulating T-cell function is established, and a series of preclinical studies provided proof-of-concept evidence of the antitumor activity of anti-CTLA-4 antibodies in combination with vaccines or chemotherapy. Subsequently, anti-CTLA-4 antibodies have shown encouraging results in clinical trials in advanced melanoma. Recent progress in the understanding of melanoma genetics and tumorgenesis has led to potential new therapeutic targets. Molecular targeted agents that inhibit the proliferation and survival of metastatic melanoma cells offer potential partners for anti-CTLA-4 antibodies in combined modality regimens [25]. Two monoclonal antibodies recognizing CTLA-4, ipilimumab (MDX 010) and tremelimumab (CP-675, 206), have been examined in many trials.

Activity of ipilimumab in patients with metastatic melanoma has been examined with and without chemotherapy. In a randomized phase II trial, ipilimumab was given alone or in combination with dacarbazine. The median overal survival (OS) for the monotherapy group was 351 and for the combination group 389 days, respectively. Approximately 10% of the patients were alive after two to more than four years of follow-up in both therapy arms. This fact indicates that the therapy can achieve a long-term control of the disease.

The activity of ipilimumab in combination with a vaccine (two modified HLA-A* 0201.restricted peptides) was tested in a randomized study (phase II) in 56 patients [26]. The overall response rate was 13%. Patients with grade 3/4 autoimmune toxicity show better clinical responses. It is reported that some of the immune-related adverse events were observed in 62% of 139 overall treated patients and were associated with a greater probability of objective antitumor response [27]. Colitis or diarrhea and also dermatitis were the most common grade 3/4 immune-related adverse events [28,29,30]. The induction of manageable autoimmunity in patients with metastatic melanoma treated with ipilimumab could be a marker of objective and durable clinical response.

Tremelimumab (CP-675, 206) is another fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD 152) in clinical development for patients with cancer [31]. In a single-arm phase II trial with 246 previously treated patients, assessing the activity of tremelimumab as a single agent shows the objective response rate of only 6.6%. The duration of response was 8.9 to 29.8 months. Clinical benefit rate (overall response + stable disease) was 21% (16 partial responses and 35 stable disease), and median overall survival was 10.0 months. Progression-free survival at six months was 15%, and survival was 40.3% at 12 months and 22% at 24 months. This indicates a role for tremelimumab in these patients [32]. A randomized study investigating tremelimumab as a single agent in comparison with a standard chemotherapy (decarbazine or temozolomide) in previously untreated patients concluded that the antibody failed to demonstrate an improvement in OS as a first-line treatment in patients with metastatic melanoma [33]. An overall response rate of 19% for a combination therapy with tremelimumab and high-dose Interferon-α2b was shown in a phase II trial of 16 previously treated patients [34]. Early-Phase clinical trials demonstrated acceptable toxicity of tremelimumab (diarrhea/colitis, dermatitis, fatigue, pancreatitis, Grave’s disease) [35].

 3.3. Vaccines

In trials involving 440 metastatic cancer patients (96% melanoma) receiving cancer vaccine, the objective response was very low (2.6%). The other 40 studies with 756 patients have showed a comparable result of 4.0% response rate [36]. It is discussable that the vaccines may only be suitable for immune-competent patients (after full resection of their tumors, adjuvant setting). However, large adjuvant trials after tumor resection (stage II-IV melanoma) have not demonstrated positive results.

3.3.1. Allogeneic and Autologous Vaccines

The autologous vaccines are prepared from tumors of individual patients. Vitespen is a tumor-derived, HSP-peptide complex vaccine that was tested in a study with 64 metastatic melanoma patients. A phase III study with 322 previously untreated metastatic melanoma patients compared Vitespen with a physician choice therapy. A similar overall survival (OS) was found in both arms [37]. In two large trials, more than 1400 patients were randomized to Canvaxin + BCG (bacillus Calmette-Guerin) or placebo + BCG after resectional surgery. The five-year survival rate in stage III was 59% for the Canvaxin patients and 68% for the placebo patients. In the stage IV study, the median survival was 32 months for the Canvaxin patients and 39 months for the placebo patients. The five-year survivals were 40% (Canvaxin) and 45% (placebo) [38,39].

3.3.2. MAGE-3

Tumor regression in melanoma patients has been documented in several trials involving antigens encoded by genes of the MAGE family, particularly MAGE-3. Low-level cytolytic lymphocyte (CTL) responses mediate these tumor regressions [40]. A randomized, open trial with the MAGE-A3 protein combined with different immunological adjuvants- AS02B or AS15- assessed the adjuvants for toxicity and clinical and immunological responses. 68 patients with unresectable stage III or stage IV M1a melanoma got the MAGE-A3 protein as first-line treatment. In combination with AS15, it yielded higher anti-MAGE-3 antibody titer, stronger T cell induction and long-lasting clinical response [41].

4. Small Molecules and Targeted Therapies

Another interesting starting point in the therapy of metastatic melanoma is the selected blocking of targeted structures. Several signal pathways related to survival of cancer cells are frequently deregulated in melanoma (RAS-RAF-MEK-ERK pathway, p16INK4A-CDK4-RB pathway, ARF-p53 pathway, PI3K-AKT pathway and the canonical Wnt signaling pathway). Inhibition of these signal transduction pathways, as well as of tumor angiogenesis, adhesion mechanisms or apoptosis induction, can be the action point of these new molecules (summarized in Table 2, see also [42]).

cancers-02-00955-t002_Table 2

Small molecules and targeted therapies used in distant metastatic melanoma.

Agent Target protein Literature
Receptor tyrosinase kinase (RTK) inhibitors
Imatinib, Dasatinib, Sunitinib, Erlotinib RTKs [43,44]
SUI1274 c-Met/HGF [45]
RAS-RAF-MEK-ERK signal pathway inhibitors
AZD6244 MEK1, 2 [46]
PD0325901 MEK1, 2 [47]
PLX4032, PLX4720 Mutant B-Raf [48,49]
Sorafenib B-Raf, c-Kit, C-Raf Flt-3, PDGF, VEGF-2 , VEGF -3 [50,51,52]
Tanespimycin Hsp90, as well as B-Raf, Akt, and others) [53]
Tipifarnib Farnesyltransferase [52]
PI3K-AKT signal pathway inhibitors
Deforolimus, Everolimus, Temsirolimus MTOR [54,55]
Perifosine, PX-866 Akt [56]
PI 103 PI3K/mTOR [57]
SB216763 GSK3beta [58]
XL765 PI3K/mTOR [59]
Targeting anti-apoptotic proteins
ABT-737 Bcl-2 group [60]
Obatoclax mesylate (GX15-070) Bcl-2 group [61]
Oblimersen sodium (G3139) Bcl-2 [62]
YM155 Survivin [63]
Targeting the neovasculature
Bevacizumab VEGF [64,65]
Axitinib (AG-013736) VEGF [66]
Others
Bortezomib (PS-341) proteasome [67,68]
Elesclomol oxidative stress induction [69]

Sorafenib is a multikinase inhibitor with selectivity for B-Raf, C-Raf, VEGFR-2 and -3, platelet-derived growth factor receptor (PDGFR) and c-Kit. Because of the high rate of activating B-Raf mutations in melanoma, sorafenib is an agent to treat metastatic melanoma. As a single agent, it has been shown to stabilize the disease in 19% of metastatic melanoma patients [70]. In contrast to sorafenib, PLX4032 is a selective inhibitor of the oncogenic V600E mutant BRAF kinase. V600E BRAF is the most common kinase mutation in melanoma (60%). Promising results in distant metastatic melanoma were recently shown for this substance [71,72].

Another interesting target is the receptor tyrosine kinase KIT. Activating Kit mutations have been found in mucosal and acral-lentiginous melanomas. Targeting Kit by receptor tyrosine-kinase inhibitors (imatinib, dasatinib, sunitinib) have shown some dramatic responses in patients with very high c-KIT expression and/or documented activating mutations [73,74,75]. This fosters the belief that focused studies in patients selected on the basis of c-KIT mutational status will yield more encouraging results.

 5. Conclusion

The prognosis of patients with metastatic malignant melanoma remains poor. Only low response rates from 10% to 25% have been achieved by the most effective single-agent chemotherapies. More aggressive chemotherapy regimens (polychemotherapies) have reached response rates of about 40% but there was no significant benefit in overall survival compared to single-agent chemotherapies. Single-agent or combination chemotherapy, new agents or biologic response modifiers alone have not yet shown response rates of durable remissions that are high enough to affect median survival. There is an urgent need for more effective agents and developing new innovative treatment options to achieve higher response rates in treatment of metastatic melanoma. There are many opportunities for improving the treatment of patients with melanoma, including novel immunotherapy approaches, molecular targeted and antiangiogenic therapies. Further efforts are needed to select treatments for patients based on tumor and host molecular and genetic features. These new substances need to be evaluated in clinical trials.

Declaims

None of the authors has financial or proprietary interests in any material or method mentioned.

 References Rass K. Hassel J.C. Chemotherapeutics, chemoresistance and the management of melanoma G. Ital. Dermatol. Venereol. 2009 144 61 78 Schadendorf D. Algarra S.M. Bastholt L. Cinat G. Dreno B. Eggermont A.M. Espinosa E. Guo J. Hauschild A. Petrella T. Schachter J. Hersey P. Immunotherapy of distant metastatic disease Ann. Oncol. 2009 20 (Suppl. 6) vi41 50 10.1093/annonc/mdp253 Balch C.M. Buzaid A.C. Soong S.J. Atkins M.B. Cascinelli N. Coit D.G. Fleming I.D. Gershenwald J.E. Houghton A. Jr. Kirkwood J.M. McMasters K.M. Mihm M.F. Morton D.L. Reintgen D.S. Ross M.I. Sober A. Thompson J.A. Thompson J.F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J. Clin. Oncol. 2001 19 3635 3648 Lee M.L. Tomsu K. Von Eschen K.B. Duration of survival for disseminated malignant melanoma: results of a meta-analysis Melanoma Res. 2000 10 81 92 Comis R.L. DTIC (NSC-45388) in malignant melanoma: a perspective Cancer Treat. Rep. 1976 60 165 176 Hill G.J. 2nd Metter G.E. Krementz E.T. Fletcher W.S. Golomb F.M. Ramirez G. Grage T.B. Moss S.E. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine Cancer Treat. Rep. 1979 63 1989 1992 Mouawad R. Sebert M. Michels J. Bloch J. Spano J.P. Khayat D. Treatment for metastatic malignant melanoma: Old drugs and new strategies Crit. Rev. Oncol. Hematol. 2009 10.1016/j.critevonc.2009.08.005 Jacquillat C. Khayat D. Banzet P. Weil M. Fumoleau P. Avril M.F. Namer M. Bonneterre J. Kerbrat P. Bonerandi J.J. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases Cancer 1990 66 1873 1878 10.1002/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5 Khayat D. Giroux B. Berille J. Cour V. Gerard B. Sarkany M. Bertrand P. Bizzari J.P. Fotemustine in the treatment of brain primary tumors and metastases Cancer Invest. 1994 12 414 420 10.3109/07357909409038234 Avril M.F. Aamdal S. Grob J.J. Hauschild A. Mohr P. Bonerandi J.J. Weichenthal M. Neuber K. Bieber T. Gilde K. Guillem Porta V. Fra J. Bonneterre J. Saiag P. Kamanabrou D. Pehamberger H. Sufliarsky J. Gonzalez Larriba J.L. Scherrer A. Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J. Clin. Oncol. 2004 22 1118 1125 10.1200/JCO.2004.04.165 Garbe C. Eigentler T.K. Therapy of malignant melanoma at the stage of distant metastasis Hautarzt 2004 55 195 213 10.1007/s00105-003-0684-1 Legha S.S. Ring S. Papadopoulos N. Plager C. Chawla S. Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma Cancer 1989 64 2024 2029 10.1002/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V Buzaid A.C. Legha S.S. Winn R. Belt R. Pollock T. Wiseman C. Ensign L.G. Cisplatin, vinblastine and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: preleminary results of a phase II Cancer Community Oncology Program (CCOP) Trial J. Clin. Oncol. 1993 12 389 Cocconi G. Bella M. Calabresi F. Tonato M. Canaletti R. Boni C. Buzzi F. Ceci G. Corgna E. Costa P. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen N. Engl. J. Med. 1992 327 516 523 10.1056/NEJM199208203270803 Ugurel S. Tilgen W. Reinhold U. Chemosensitivity testing in malignant melanoma Recent Results Cancer Res. 2003 161 81 92 10.1007/978-3-642-19022-3_8 Ugurel S. Schadendorf D. Pfohler C. Neuber K. Thoelke A. Ulrich J. Hauschild A. Spieth K. Kaatz M. Rittgen W. Delorme S. Tilgen W. Reinhold U. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group Clin. Cancer Res. 2006 12 5454 5463 10.1158/1078-0432.CCR-05-2763 Huncharek M. Caubet J.F. McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials Melanoma Res. 2001 11 75 81 10.1097/00008390-200102000-00009 Garbe C. Hauschild A. Volkenandt M. Schadendorf D. Stolz W. Reinhold U. Kortmann R.D. Kettelhack C. Frerich B. Keilholz U. Dummer R. Sebastian G. Tilgen W. Schuler G. Mackensen A. Kaufmann R. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting Melanoma Res. 2008 18 152 160 10.1097/CMR.0b013e3282f702bf Atkins M.B. Lotze M.T. Dutcher J.P. Fisher R.I. Weiss G. Margolin K. Abrams J. Sznol M. Parkinson D. Hawkins M. Paradise C. Kunkel L. Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J. Clin. Oncol. 1999 17 2105 2116 Tsao H. Atkins M.B. Sober A.J. Management of cutaneous melanoma N. Engl. J. Med. 2004 351 998 1012 10.1056/NEJMra041245 Slaton J.W. Perrotte P. Inoue K. Dinney C.P. Fidler I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule Clin. Cancer Res. 1999 5 2726 2734 Hakansson A. Gustafsson B. Krysander L. Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma J. Interferon Cytokine Res. 1998 18 33 39 10.1089/jir.1998.18.33 Agarwala S.S. Kirkwood J.M. Interferons in melanoma Curr. Opin. Oncol. 1996 8 167 174 10.1097/00001622-199603000-00015 Agarwala S.S. Kirkwood J.M. Potential uses of interferon alpha 2 as adjuvant therapy in cancer Ann. Surg. Oncol. 1995 2 365 371 10.1007/BF02307071 Agarwala S.S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma Melanoma Res. 2010 20 1 10 10.1097/CMR.0b013e328333bbc8 Attia P. Phan G.Q. Maker A.V. Robinson M.R. Quezado M.M. Yang J.C. Sherry R.M. Topalian S.L. Kammula U.S. Royal R.E. Restifo N.P. Haworth L.R. Levy C. Mavroukakis S.A. Nichol G. Yellin M.J. Rosenberg S.A. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J. Clin. Oncol. 2005 23 6043 6053 10.1200/JCO.2005.06.205 Downey S.G. Klapper J.A. Smith F.O. Yang J.C. Sherry R.M. Royal R.E. Kammula U.S. Hughes M.S. Allen T.E. Levy C.L. Yellin M. Nichol G. White D.E. Steinberg S.M. Rosenberg S.A. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin. Cancer Res. 2007 13 6681 6688 10.1158/1078-0432.CCR-07-0187 Beck K.E. Blansfield J.A. Tran K.Q. Feldman A.L. Hughes M.S. Royal R.E. Kammula U.S. Topalian S.L. Sherry R.M. Kleiner D. Quezado M. Lowy I. Yellin M. Rosenberg S.A. Yang J.C. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J. Clin. Oncol. 2006 24 2283 2289 10.1200/JCO.2005.04.5716 O'Day S.J. Maio M. Chiarion-Sileni V. Gajewski T.F. Pehamberger H. Bondarenko I.N. Queirolo P. Lundgren L. Mikhailov S. Roman L. Verschraegen C. Humphrey R. Ibrahim R. de Pril V. Hoos A. Wolchok J.D. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann. Oncol. 2010 10.1093/annonc/mdq013 Wolchok J.D. Neyns B. Linette G. Negrier S. Lutzky J. Thomas L. Waterfield W. Schadendorf D. Smylie M. Guthrie T. Jr. Grob J.J. Chesney J. Chin K. Chen K. Hoos A. O'Day S.J. Lebbe C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol. 2010 11 155 164 10.1016/S1470-2045(09)70334-1 Ribas A. Hanson D.C. Noe D.A. Millham R. Guyot D.J. Bernstein S.H. Canniff P.C. Sharma A. Gomez-Navarro J. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer Oncologist 2007 12 873 883 10.1634/theoncologist.12-7-873 Kirkwood J.M. Lorigan P. Hersey P. Hauschild A. Robert C. McDermott D. Marshall M.A. Gomez-Navarro J. Liang J.Q. Bulanhagui C.A. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin. Cancer Res. 2010 16 1042 1048 10.1158/1078-0432.CCR-09-2033 Ribas A. Hauschild A. Kefford R. Punt C.J. Haanen J.B. Marmol M. Garbe C. Gomez-Navarro J. Pavlov D. Mars M. Phase III, open-lable, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC] in patients with advanced melanoma. ASCO annual proceedings Part I J. Clin. Oncol. 2008 26 Abstr. LBA9011 Tarhini A.A. Moschos S.S. Schlesselman J.J. Shope-Spotloe J. Demark M. Kirkwood J.M. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. ASCO Annual proceedings Part I J. Clin. Oncol. 2008 26 Abstr. 9009 Ribas A. Antonia S. Sosman J. Results of a phase II clinical trial of 2 doses and schedules of CP-675, 206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. ASCO Annual Meeting Proceedings Part I J. Clin. Oncol. 2007 25 Abstr. 3000 Rosenberg S.A. Yang J.C. Restifo N.P. Cancer immunotherapy: moving beyond current vaccines Nat. Med. 2004 10 909 915 10.1038/nm1100 Testori A. Richards J. Whitman E. Mann G.B. Lutzky J. Camacho L. Parmiani G. Tosti G. Kirkwood J.M. Hoos A. Yuh L. Gupta R. Srivastava P.K. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group J. Clin. Oncol. 2008 26 955 962 10.1200/JCO.2007.11.9941 Chung M.H. Gupta R.K. Hsueh E. Essner R. Ye W. Yee R. Morton D.L. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy J. Clin. Oncol. 2003 21 313 319 10.1200/JCO.2003.10.068 Hsueh E.C. Essner R. Foshag L.J. Ollila D.W. Gammon G. O'Day S.J. Boasberg P.D. Stern S.L. Ye X. Morton D.L. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine J. Clin. Oncol. 2002 20 4549 4554 10.1200/JCO.2002.01.151 Coulie P.G. Karanikas V. Colau D. Lurquin C. Landry C. Marchand M. Dorval T. Brichard V. Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 Proc. Natl. Acad. Sci. USA 2001 98 10290 10295 Kruit W.H. Suciu S. Dreno B. Chiarion-Sileni V. Mortier L. Robert C. Maio M. Brichard V.G. Lehmann F. Keilholz U. immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-lable phase II study of the EORTC Melanoma Group (16032-18031). ASCO Annual Proceedings Part I J. Clin. Oncol. 2008 26 Abstr. 9065 Hersey P. Bastholt L. Chiarion-Sileni V. Cinat G. Dummer R. Eggermont A.M. Espinosa E. Hauschild A. Quirt I. Robert C. Schadendorf D. Small molecules and targeted therapies in distant metastatic disease Ann. Oncol. 2009 20 (Suppl. 6) vi35 40 10.1093/annonc/mdp254 Hodi F.S. Friedlander P. Corless C.L. Heinrich M.C. Mac Rae S. Kruse A. Jagannathan J. Van den Abbeele A.D. Velazquez E.F. Demetri G.D. Fisher D.E. Major response to imatinib mesylate in KIT-mutated melanoma J. Clin. Oncol. 2008 26 2046 2051 10.1200/JCO.2007.14.0707 Woodman S.E. Trent J.C. Stemke-Hale K. Lazar A.J. Pricl S. Pavan G.M. Fermeglia M. Gopal Y.N. Yang D. Podoloff D.A. Ivan D. Kim K.B. Papadopoulos N. Hwu P. Mills G.B. Davies M.A. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates Mol. Cancer Ther. 2009 8 2079 2085 10.1158/1535-7163.MCT-09-0459 Puri N. Ahmed S. Janamanchi V. Tretiakova M. Zumba O. Krausz T. Jagadeeswaran R. Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma Clin. Cancer Res. 2007 13 2246 2253 10.1158/1078-0432.CCR-06-0776 Adjei A.A. Cohen R.B. Franklin W. Morris C. Wilson D. Molina J.R. Hanson L.J. Gore L. Chow L. Leong S. Maloney L. Gordon G. Simmons H. Marlow A. Litwiler K. Brown S. Poch G. Kane K. Haney J. Eckhardt S.G. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J. Clin. Oncol. 2008 26 2139 2146 10.1200/JCO.2007.14.4956 Ciuffreda L. Del Bufalo D. Desideri M. Di Sanza C. Stoppacciaro A. Ricciardi M.R. Chiaretti S. Tavolaro S. Benassi B. Bellacosa A. Foa R. Tafuri A. Cognetti F. Anichini A. Zupi G. Milella M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations Neoplasia 2009 11 720 731 Halaban R. Zhang W. Bacchiocchi A. Cheng E. Parisi F. Ariyan S. Krauthammer M. McCusker J.P. Kluger Y. Sznol M. PLX4032, a Selective BRAF(V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF(WT) Melanoma Cells Pigment Cell Melanoma Res. 2010 23 190 200 10.1111/j.1755-148X.2010.00685.x Tsai J. Lee J.T. Wang W. Zhang J. Cho H. Mamo S. Bremer R. Gillette S. Kong J. Haass N.K. Sproesser K. Li L. Smalley K.S. Fong D. Zhu Y.L. Marimuthu A. Nguyen H. Lam B. Liu J. Cheung I. Rice J. Suzuki Y. Luu C. Settachatgul C. Shellooe R. Cantwell J. Kim S.H. Schlessinger J. Zhang K.Y. West B.L. Powell B. Habets G. Zhang C. Ibrahim P.N. Hirth P. Artis D.R. Herlyn M. Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. USA 2008 105 3041 3046 10.1073/pnas.0711741105 Amaravadi R.K. Schuchter L.M. McDermott D.F. Kramer A. Giles L. Gramlich K. Carberry M. Troxel A.B. Letrero R. Nathanson K.L. Atkins M.B. O'Dwyer P.J. Flaherty K.T. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases Clin. Cancer Res. 2009 15 7711 7718 10.1158/1078-0432.CCR-09-2074 Hauschild A. Agarwala S.S. Trefzer U. Hogg D. Robert C. Hersey P. Eggermont A. Grabbe S. Gonzalez R. Gille J. Peschel C. Schadendorf D. Garbe C. O'Day S. Daud A. White J.M. Xia C. Patel K. Kirkwood J.M. Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J. Clin. Oncol. 2009 27 2823 2830 10.1200/JCO.2007.15.7636 Hong D.S. Sebti S.M. Newman R.A. Blaskovich M.A. Ye L. Gagel R.F. Moulder S. Wheler J.J. Naing A. Tannir N.M. Ng C.S. Sherman S.I. El Naggar A.K. Khan R. Trent J. Wright J.J. Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies Clin. Cancer Res. 2009 15 7061 7068 10.1158/1078-0432.CCR-09-1241 Kefford R. Millward M. Hersey P. Brady B. Graham M. Johnson R.G. Hannah A.L. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. ASCO Annual Meeting Proceedings Part I J. Clin. Oncol. 2007 25 (18S, June 20 Supplement) 8558 Mita M.M. Britten C.D. Poplin E. Tap W.D. Carmona A. Yonemoto L. Wages D.S. Bedrosian C.L. Rubin E.H. Tolcher A.W. Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669) J. Clin. Oncol. 2008 26 Abstr. 3509 Thallinger C. Werzowa J. Poeppl W. Kovar F.M. Pratscher B. Valent P. Quehenberger P. Joukhadar C. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice J. Invest. Dermatol. 2007 127 2411 2417 10.1038/sj.jid.5700872 Ernst D.S. Eisenhauer E. Wainman N. Davis M. Lohmann R. Baetz T. Belanger K. Smylie M. Phase II study of perifosine in previously untreated patients with metastatic melanoma Invest. New Drugs 2005 23 569 575 10.1007/s10637-005-1157-4 Lopez-Fauqued M. Gil R. Grueso J. Hernandez-Losa J. Pujol A. Moline T. Recio J.A. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells Int. J. Cancer 2010 126 1549 1561 Smalley K.S. Contractor R. Haass N.K. Kulp A.N. Atilla-Gokcumen G.E. Williams D.S. Bregman H. Flaherty K.T. Soengas M.S. Meggers E. Herlyn M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells Cancer Res. 2007 67 209 217 10.1158/0008-5472.CAN-06-1538 Papadopoulos K.P. Markman B. Tabernero J. Patnaik A. Heath E.I. DeCillis A. Laird D. Aggarwal S.K. Nguyen L. LoRusso P.M. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors J. Clin. Oncol. 2008 26 Abstr. 3510 Weber A. Kirejczyk Z. Potthoff S. Ploner C. Hacker G. Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells Transl. Oncol. 2009 2 73 83 Jiang C.C. Yang F. Thorne R.F. Zhu B.K. Hersey P. Zhang X.D. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt Neoplasia 2009 11 436 447 Bedikian A.Y. Millward M. Pehamberger H. Conry R. Gore M. Trefzer U. Pavlick A.C. DeConti R. Hersh E.M. Hersey P. Kirkwood J.M. Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group J. Clin. Oncol. 2006 24 4738 4745 10.1200/JCO.2006.06.0483 Lewis K.D. Samlowski W. Ward J. Catlett J. Cranmer L. Kirkwood J. Lawson D. Whitman E. Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma Invest. New Drugs 2009 10.1007/s10637-009-9333-6 Perez D.G. Suman V.J. Fitch T.R. Amatruda T. 3rd Morton R.F. Jilani S.Z. Constantinou C.L. Egner J.R. Kottschade L.A. Markovic S.N. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A Cancer 2009 115 119 127 10.1002/cncr.23987 Schicher N. Paulitschke V. Swoboda A. Kunstfeld R. Loewe R. Pilarski P. Pehamberger H. Hoeller C. Erlotinib and bevacizumab have synergistic activity against melanoma Clin. Cancer Res. 2009 15 3495 3502 10.1158/1078-0432.CCR-08-2407 Kelly R.J. Rixe O. Axitinib (AG-013736) Recent Results Cancer Res. 2010 184 33 44 10.1007/978-3-642-01222-8_3 Seeger J.M. Schmidt P. Brinkmann K. Hombach A.A. Coutelle O. Zigrino P. Wagner-Stippich D. Mauch C. Abken H. Kronke M. Kashkar H. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack Cancer Res. 2010 70 1825 1834 10.1158/0008-5472.CAN-09-3175 Su Y. Amiri K.I. Horton L.W. Yu Y. Ayers G.D. Koehler E. Kelley M.C. Puzanov I. Richmond A. Sosman J.A. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets Clin. Cancer Res. 2010 16 348 357 10.1158/1078-0432.CCR-09-2087 O'Day S. Gonzalez R. Lawson D. Weber R. Hutchins L. Anderson C. Haddad J. Kong S. Williams A. Jacobson E. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma J. Clin. Oncol. 2009 27 5452 5458 10.1200/JCO.2008.17.1579 Flaherty K.T. Chemotherapy and targeted therapy combinations in advanced melanoma Clin. Cancer Res. 2006 12 2366 2370 10.1158/1078-0432.CCR-05-2505 Flaherty K. Puzanov I. Sosman J. Kim K. Ribas A. McArthur G. Lee R. J. Grippo J.F. Nolop K. Chapman P. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer J. Clin. Oncol. 2009 27 (Suppl. 15s) Abstr. 9000 Puzanov I. Nathanson K.L. Chapman P.B. Xu X. Sosman J.A. McArthur G.A. Ribas A. Kim K.B. Grippo J.F. Flaherty K.T. PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial J. Clin. Oncol. 2009 27 (Suppl. 15s) Abstr. 9021 Becker J.C. Brocker E.B. Schadendorf D. Ugurel S. Imatinib in melanoma: a selective treatment option based on KIT mutation status? J. Clin. Oncol. 2007 25 e9 10.1200/JCO.2006.08.9664 Carvajal R.D. Chapman P.B. Wolchok J.D. Cane L. Teitcher J.B. Lutzky J. Pavlick A.C. Bastian B.C. Antonescu C.R. Schwartz G.K. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT J. Clin. Oncol. 2009 27 (suppl. 15s) Abstr. 9001 Garrido M.C. Bastian B.C. KIT as a therapeutic target in melanoma J. Invest Dermatol. 2010 130 20 27 10.1038/jid.2009.334